UTHR logo

United Therapeutics (UTHR) Cash from operations

annual CFO:

$1.33B+$349.10M(+35.70%)
December 31, 2024

Summary

  • As of today (May 29, 2025), UTHR annual cash flow from operations is $1.33 billion, with the most recent change of +$349.10 million (+35.70%) on December 31, 2024.
  • During the last 3 years, UTHR annual CFO has risen by +$728.90 million (+121.85%).
  • UTHR annual CFO is now at all-time high.

Performance

UTHR Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherUTHRcash flow metrics

quarterly CFO:

$461.20M+$120.00M(+35.17%)
March 31, 2025

Summary

  • As of today (May 29, 2025), UTHR quarterly cash flow from operations is $461.20 million, with the most recent change of +$120.00 million (+35.17%) on March 31, 2025.
  • Over the past year, UTHR quarterly CFO has increased by +$84.70 million (+22.50%).
  • UTHR quarterly CFO is now at all-time high.

Performance

UTHR quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherUTHRcash flow metrics

TTM CFO:

$1.41B+$84.70M(+6.38%)
March 31, 2025

Summary

  • As of today (May 29, 2025), UTHR TTM cash flow from operations is $1.41 billion, with the most recent change of +$84.70 million (+6.38%) on March 31, 2025.
  • Over the past year, UTHR TTM CFO has increased by +$432.10 million (+44.11%).
  • UTHR TTM CFO is now at all-time high.

Performance

UTHR TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherUTHRcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

UTHR Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+35.7%+22.5%+44.1%
3 y3 years+121.8%+59.8%+77.1%
5 y5 years+742.4%+114.9%+122.2%

UTHR Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+121.8%at high+333.9%at high+82.0%
5 y5-yearat high+742.4%at high+413.6%at high+156.8%
alltimeall timeat high+742.4%at high+173.5%at high+731.1%

UTHR Cash from operations History

DateAnnualQuarterlyTTM
Mar 2025
-
$461.20M(+35.2%)
$1.41B(+6.4%)
Dec 2024
$1.33B(+35.7%)
$341.20M(-9.5%)
$1.33B(+16.8%)
Sep 2024
-
$377.20M(+62.4%)
$1.14B(+2.8%)
Jun 2024
-
$232.20M(-38.3%)
$1.11B(+12.9%)
Mar 2024
-
$376.50M(+149.8%)
$979.70M(+0.2%)
Dec 2023
$978.00M(+21.9%)
$150.70M(-56.5%)
$978.00M(+2.4%)
Sep 2023
-
$346.20M(+225.7%)
$955.50M(+10.1%)
Jun 2023
-
$106.30M(-71.6%)
$867.90M(-2.3%)
Mar 2023
-
$374.80M(+192.4%)
$888.60M(+10.7%)
Dec 2022
$802.50M(+34.2%)
$128.20M(-50.4%)
$802.50M(-5.5%)
Sep 2022
-
$258.60M(+103.6%)
$848.90M(+9.4%)
Jun 2022
-
$127.00M(-56.0%)
$775.90M(-2.7%)
Mar 2022
-
$288.70M(+65.3%)
$797.10M(+33.2%)
Dec 2021
$598.20M(-20.8%)
$174.60M(-5.9%)
$598.20M(+8.8%)
Sep 2021
-
$185.60M(+25.2%)
$549.80M(-10.6%)
Jun 2021
-
$148.20M(+65.0%)
$615.10M(-2.5%)
Mar 2021
-
$89.80M(-28.8%)
$630.90M(-16.5%)
Dec 2020
$755.70M(-465.8%)
$126.20M(-49.7%)
$755.70M(+3.2%)
Sep 2020
-
$250.90M(+53.0%)
$732.00M(+9.8%)
Jun 2020
-
$164.00M(-23.6%)
$666.50M(+4.9%)
Mar 2020
-
$214.60M(+109.4%)
$635.40M(-407.6%)
Dec 2019
-$206.60M(-126.5%)
$102.50M(-44.7%)
-$206.60M(-7.6%)
Sep 2019
-
$185.40M(+39.5%)
-$223.70M(+30.4%)
Jun 2019
-
$132.90M(-121.2%)
-$171.60M(+37.6%)
Mar 2019
-
-$627.40M(-834.7%)
-$124.70M(-116.0%)
Dec 2018
$778.40M(+64.2%)
$85.40M(-64.0%)
$778.40M(+28.2%)
Sep 2018
-
$237.50M(+32.1%)
$607.20M(-3.3%)
Jun 2018
-
$179.80M(-34.8%)
$628.20M(+21.0%)
Mar 2018
-
$275.70M(-421.3%)
$519.10M(+9.5%)
Dec 2017
$474.20M(-26.3%)
-$85.80M(-133.2%)
$474.20M(-34.4%)
Sep 2017
-
$258.50M(+265.6%)
$723.40M(+4.3%)
Jun 2017
-
$70.70M(-69.4%)
$693.60M(-7.3%)
Mar 2017
-
$230.80M(+41.2%)
$748.60M(+16.3%)
Dec 2016
$643.60M(+68.1%)
$163.40M(-28.6%)
$643.60M(+27.3%)
Sep 2016
-
$228.70M(+81.9%)
$505.70M(+4.4%)
Jun 2016
-
$125.70M(-0.1%)
$484.20M(+21.2%)
Mar 2016
-
$125.80M(+393.3%)
$399.50M(+4.4%)
Dec 2015
$382.80M(+7.7%)
$25.50M(-87.7%)
$382.80M(-14.5%)
Sep 2015
-
$207.20M(+405.4%)
$447.95M(-0.3%)
Jun 2015
-
$41.00M(-62.4%)
$449.28M(+27.0%)
Mar 2015
-
$109.10M(+20.4%)
$353.80M(-0.4%)
Dec 2014
$355.30M(-16.5%)
$90.65M(-56.5%)
$355.30M(-3.7%)
Sep 2014
-
$208.54M(-482.8%)
$369.07M(+23.1%)
Jun 2014
-
-$54.48M(-149.3%)
$299.84M(-31.6%)
Mar 2014
-
$110.60M(+5.9%)
$438.17M(+3.0%)
Dec 2013
$425.27M(+31.4%)
$104.42M(-25.0%)
$425.27M(-0.2%)
Sep 2013
-
$139.30M(+66.1%)
$426.06M(+12.1%)
Jun 2013
-
$83.85M(-14.2%)
$380.20M(-0.9%)
Mar 2013
-
$97.70M(-7.1%)
$383.74M(+18.6%)
Dec 2012
$323.63M(+29.4%)
$105.21M(+12.6%)
$323.63M(+19.8%)
Sep 2012
-
$93.45M(+6.9%)
$270.05M(+5.0%)
Jun 2012
-
$87.39M(+132.5%)
$257.28M(+9.7%)
Mar 2012
-
$37.59M(-27.2%)
$234.43M(-6.3%)
DateAnnualQuarterlyTTM
Dec 2011
$250.19M(+18.3%)
$51.63M(-36.0%)
$250.19M(+5.2%)
Sep 2011
-
$80.68M(+25.0%)
$237.82M(-8.5%)
Jun 2011
-
$64.54M(+21.0%)
$259.97M(+12.7%)
Mar 2011
-
$53.35M(+35.9%)
$230.66M(+9.0%)
Dec 2010
$211.53M(+112.1%)
$39.25M(-61.8%)
$211.53M(+6.5%)
Sep 2010
-
$102.83M(+191.9%)
$198.60M(+77.7%)
Jun 2010
-
$35.23M(+3.0%)
$111.76M(-14.0%)
Mar 2010
-
$34.22M(+30.0%)
$129.91M(+30.3%)
Dec 2009
$99.72M(-302.7%)
$26.32M(+64.6%)
$99.72M(-286.3%)
Sep 2009
-
$15.99M(-70.0%)
-$53.54M(-8.0%)
Jun 2009
-
$53.38M(+1222.2%)
-$58.19M(-27.4%)
Mar 2009
-
$4.04M(-103.2%)
-$80.19M(+63.0%)
Dec 2008
-$49.20M(-200.5%)
-$126.94M(-1219.6%)
-$49.20M(-174.5%)
Sep 2008
-
$11.34M(-63.9%)
$66.05M(-19.5%)
Jun 2008
-
$31.38M(-10.4%)
$82.01M(+17.0%)
Mar 2008
-
$35.03M(-399.5%)
$70.07M(+43.2%)
Dec 2007
$48.95M(-0.9%)
-$11.70M(-142.8%)
$48.95M(-9.6%)
Sep 2007
-
$27.31M(+40.5%)
$54.13M(+19.3%)
Jun 2007
-
$19.43M(+39.8%)
$45.37M(-3.1%)
Mar 2007
-
$13.90M(-313.5%)
$46.81M(-5.2%)
Dec 2006
$49.39M(+14.4%)
-$6.51M(-135.1%)
$49.39M(-22.2%)
Sep 2006
-
$18.54M(-11.2%)
$63.47M(+5.6%)
Jun 2006
-
$20.88M(+26.7%)
$60.12M(+10.3%)
Mar 2006
-
$16.48M(+117.6%)
$54.50M(+26.3%)
Dec 2005
$43.17M(+107.7%)
$7.57M(-50.1%)
$43.17M(+11.0%)
Sep 2005
-
$15.19M(-0.5%)
$38.89M(+16.6%)
Jun 2005
-
$15.26M(+196.2%)
$33.36M(+30.4%)
Mar 2005
-
$5.15M(+56.2%)
$25.59M(+23.2%)
Dec 2004
$20.78M(-342.7%)
$3.30M(-65.9%)
$20.78M(+229.2%)
Sep 2004
-
$9.66M(+29.0%)
$6.31M(+515.7%)
Jun 2004
-
$7.49M(+2114.8%)
$1.02M(-113.2%)
Mar 2004
-
$338.00K(-103.0%)
-$7.79M(-9.0%)
Dec 2003
-$8.56M(-61.5%)
-$11.17M(-355.5%)
-$8.56M(-397.5%)
Sep 2003
-
$4.37M(-427.9%)
$2.88M(-135.1%)
Jun 2003
-
-$1.33M(+210.0%)
-$8.19M(-42.2%)
Mar 2003
-
-$430.00K(-259.3%)
-$14.17M(-36.3%)
Dec 2002
-$22.26M(-42.8%)
$270.00K(-104.0%)
-$22.26M(-25.6%)
Sep 2002
-
-$6.70M(-8.4%)
-$29.91M(-15.0%)
Jun 2002
-
-$7.31M(-14.2%)
-$35.18M(-9.4%)
Mar 2002
-
-$8.52M(+15.5%)
-$38.82M(-0.2%)
Dec 2001
-$38.90M(+25.0%)
-$7.38M(-38.4%)
-$38.90M(-6.4%)
Sep 2001
-
-$11.97M(+9.3%)
-$41.54M(+19.8%)
Jun 2001
-
-$10.96M(+27.5%)
-$34.67M(+6.3%)
Mar 2001
-
-$8.59M(-14.2%)
-$32.61M(+4.8%)
Dec 2000
-$31.11M(+31.3%)
-$10.02M(+96.6%)
-$31.11M(+8.1%)
Sep 2000
-
-$5.10M(-42.7%)
-$28.79M(-1.4%)
Jun 2000
-
-$8.89M(+25.2%)
-$29.20M(+5.0%)
Mar 2000
-
-$7.10M(-7.7%)
-$27.80M(+17.3%)
Dec 1999
-$23.70M(+146.9%)
-$7.70M(+40.0%)
-$23.70M(+48.1%)
Sep 1999
-
-$5.50M(-26.7%)
-$16.00M(+52.4%)
Jun 1999
-
-$7.50M(+150.0%)
-$10.50M(+250.0%)
Mar 1999
-
-$3.00M
-$3.00M
Dec 1998
-$9.60M
-
-

FAQ

  • What is United Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for United Therapeutics?
  • What is United Therapeutics annual CFO year-on-year change?
  • What is United Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for United Therapeutics?
  • What is United Therapeutics quarterly CFO year-on-year change?
  • What is United Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for United Therapeutics?
  • What is United Therapeutics TTM CFO year-on-year change?

What is United Therapeutics annual cash flow from operations?

The current annual CFO of UTHR is $1.33B

What is the all time high annual CFO for United Therapeutics?

United Therapeutics all-time high annual cash flow from operations is $1.33B

What is United Therapeutics annual CFO year-on-year change?

Over the past year, UTHR annual cash flow from operations has changed by +$349.10M (+35.70%)

What is United Therapeutics quarterly cash flow from operations?

The current quarterly CFO of UTHR is $461.20M

What is the all time high quarterly CFO for United Therapeutics?

United Therapeutics all-time high quarterly cash flow from operations is $461.20M

What is United Therapeutics quarterly CFO year-on-year change?

Over the past year, UTHR quarterly cash flow from operations has changed by +$84.70M (+22.50%)

What is United Therapeutics TTM cash flow from operations?

The current TTM CFO of UTHR is $1.41B

What is the all time high TTM CFO for United Therapeutics?

United Therapeutics all-time high TTM cash flow from operations is $1.41B

What is United Therapeutics TTM CFO year-on-year change?

Over the past year, UTHR TTM cash flow from operations has changed by +$432.10M (+44.11%)
On this page